News
Six researchers at The Royal Marsden NHS Foundation Trust and our partner academic institution, The Institute of Cancer Research, London (ICR), have been named in a list of the world's most influential and innovative researchers over the last decade.
Combining two existing cancer drugs could offer promise for some children with an incurable childhood brain cancer, a new study suggests.
The Royal Marsden NHS Foundation Trust will establish a state-of-the-art liquid biopsy testing facility for cancer clinical diagnostics and research following a partnership with Guardant Health, a leading precision oncology company.
Fiona MacNeill, a consultant oncoplastic breast surgeon at The Royal Marsden NHS Foundation Trust, and National Clinical Lead for Breast Surgery has co-authored a national report into breast surgery services which aims to improve care and outcomes for thousands of patients across England.
Researchers at The Royal Marsden, Francis Crick Institute and University College London (UCL) have found immune cell patterns within tumours that can help predict whether patients with kidney cancer will respond to immunotherapy. Results from the ADAPTeR clinical trial were published in Cancer Cell journal today, 28th October 2021.
A third dose of the COVID-19 vaccine could increase protection from COVID-19 for people with cancer, and especially blood cancer, according to a new study from the Francis Crick Institute and The Royal Marsden NHS Foundation Trust published today in Nature Cancer (27 October).
We have launched our flu campaign to vaccinate staff working closely with patients.
Opening in 2022, the Oak Cancer Centre (OCC) in Sutton will speed up the translation of world-leading research into breakthroughs in treatment and care, transforming the lives of cancer patients at The Royal Marsden and beyond.
Scientists at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research (ICR) used artificial intelligence-enhanced tools to successfully propose a new combination of drugs for use against an incurable childhood brain cancer.
A novel tool designed by clinicians from The Royal Marsden has facilitated intensive care (ICU) patients to receive earlier access to palliative care. Use of the tool has increased referrals from intensive care unit (ICU) to palliative care by 46%, according to data from its first year of implementation in the hospital1.